Quick Answer
NeuroSense Therapeutics Ltd. reported Stockholders Equity of -$1.56 million for the year ending 2025.
- NeuroSense Therapeutics Ltd. showed a decrease of -160.4% in Stockholders Equity from 2024 to 2025.
- This data is from NeuroSense Therapeutics Ltd.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), NeuroSense Therapeutics Ltd.'s Stockholders Equity has declined by 114.4%.
- Historical annual values: Fiscal year 2025: -$1.56 million | Fiscal year 2024: $2.58 million | Fiscal year 2023: -$1.76 million | Fiscal year 2022: $5.84 million | Fiscal year 2021: $10.83 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: